Ki-67(MIB-1), Pulmonary, Quantitative Immunohistochemistry, Automated
Use
The test is useful for determining the proliferation of tumor cells in paraffin-embedded tissue blocks from patients diagnosed with carcinoid or atypical carcinoid of the lung, including metastases. By measuring the presence of Ki-67 antigen, it provides an estimate of DNA synthesis, which may offer prognostic information across various tumor types.
Special Instructions
Attach the green "Attention Pathology" address label (T498) to the transport container before shipping. Pathologist's name, address, and phone number, along with an accompanying pathology report stating the final diagnosis, are required.
Limitations
The paraffin block analyzed must be representative of the patient's tumor. Test results should be interpreted in the context of clinical findings and other laboratory data. Any nucleus forming an antigen-antibody complex with the diaminobenzidine (DAB) chromogen is evaluated, and test accuracy largely depends on proper specimen collection and handling.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
LOINC Codes
- 29593-1
- 29593-1
- 19139-5
- 81178-6
- 62364-5
- 80398-1
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Pathology Packaging Kit
Collection Instructions
Submit formalin-fixed, paraffin-embedded tissue block. Acceptable are two unstained sections on charged slides, fixed in 10% neutral buffered formalin, cut at 4 microns <1 month ago.
Causes for Rejection
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.